What the push for testosterone therapy really means for everyday men
A calm look at the US push for testosterone testing and UK policy changes, what the evidence says and what you can do this week.
According to Health, the US defence secretary has called for routine testosterone testing of soldiers and the US health secretary has lifted prescribing limits on testosterone replacement therapy (TRT). The proposals raise questions about whether men who feel fine should start a hormone regimen and what the NHS might face if similar ideas spread.
Why testosterone matters – a brief background
Testosterone is the primary male sex hormone. In healthy adult men it circulates at about 10–30 nmol/L, peaks in the early 20s and falls roughly 1 % per year thereafter. Low levels – medically called hypogonadism – can cause fatigue, reduced muscle mass, loss of bone density and a diminished sex drive. In the NHS, TRT is approved only when two separate blood tests confirm a level below the laboratory reference range and the man reports relevant symptoms. The policy is designed to avoid treating men whose natural decline is still within the normal range.
How TRT is supposed to work
TRT adds exogenous testosterone via injection, gel, patch or implant, raising serum levels to the upper‑normal range. The hormone binds to androgen receptors in muscle, bone and the brain, stimulating protein synthesis, increasing red‑blood‑cell production and influencing mood pathways. In theory, this can improve strength, bone mineral density and libido. The body, however, reduces its own production in response – a feedback loop that can shrink the testes over time. Because the dose is set to mimic natural levels, side‑effects are often subtle, but they can include acne, fluid retention and an increase in haematocrit (the proportion of red blood cells), which raises clot risk.
What the evidence suggests about benefits and harms
Randomised trials in men with confirmed hypogonadism show modest gains in lean muscle mass (around 1–2 kg over a year) and small improvements in bone density. Subjective reports of energy and sexual desire also tend to rise, but the effect size varies widely. Large‑scale observational studies have linked TRT to a higher incidence of cardiovascular events, especially in men over 65, though the causal link remains debated. Prostate‑cancer risk has not been shown to increase in robust trials, but the therapy can raise prostate‑specific antigen (PSA) levels, prompting more frequent screening.
The overall picture is mixed: the evidence suggests clear benefit for men with a genuine deficiency, but for those whose levels are merely at the low‑normal end the balance of benefit versus risk is uncertain.
Comparing the main approaches
| Option | Typical indication | Main potential benefit | Main known risk | How the NHS views it |
|---|---|---|---|---|
| No TRT | Normal ageing, no symptoms | Avoids medication side‑effects | Possible missed treatment if deficiency exists | Default – no prescription without confirmed hypogonadism |
| TRT for diagnosed hypogonadism | Two low blood tests + symptoms | Improves muscle, bone, libido in deficient men | Cardiovascular, haematocrit rise, need for regular monitoring | Supported, but only with strict diagnostic criteria |
| Off‑label TRT for performance or “optimisation” | Low‑normal testosterone, no medical indication | Slight increase in strength, possible mood lift | Unclear long‑term safety, suppression of natural production, monitoring burden | Not recommended; prescribing would be off‑label and NHS would not fund |
Who stands to gain – and who may lose
- Soldiers and athletes could see short‑term performance gains, but the trade‑off is a higher chance of adverse events and the need for ongoing medical oversight.
- Men with genuine hypogonadism are the group most likely to experience real health improvements, provided they are monitored.
- Pharmaceutical companies would benefit from a larger market, especially if the definition of “low testosterone” expands.
- The NHS could face increased demand for blood tests, specialist appointments and long‑term monitoring, stretching resources that are already tight.
- Men without a medical indication risk exposing themselves to side‑effects for marginal gains, and may create a cultural pressure to “optimise” a hormone that naturally declines.
What could go wrong or remain unknown
The Guardian piece points out that policy moves can outpace the science. Lifting prescribing limits may lead to more men requesting TRT simply because it becomes easier to obtain, not because they meet clinical criteria. Long‑term data on cardiovascular outcomes beyond ten years are still sparse, especially for younger, otherwise healthy men. Monitoring requirements – regular blood pressure, haematocrit and PSA checks – place an administrative burden on both patients and clinics. Finally, the cultural narrative that higher testosterone equals better masculinity can reinforce stigma around natural ageing and discourage men from seeking help for non‑hormonal issues such as mental health or sleep quality.
A practical step you can take this week
If you’re curious about your testosterone level, start by listing any symptoms you experience – low energy, reduced strength, mood changes or loss of libido. Book a routine appointment with your GP and discuss whether a blood test is warranted before you consider any hormone treatment. In most cases, simple lifestyle tweaks – regular resistance training, adequate protein (about 1.2 g per kg body weight), sufficient sleep (7–9 hours) and stress management – can raise natural testosterone by 10–20 % and improve the same outcomes that TRT aims to address, without the need for medication.
